<DOC>
	<DOCNO>NCT00434317</DOCNO>
	<brief_summary>This study evaluate safety , tolerability efficacy zoledronic acid administer intravenously every 3-4 week patient bone metastases either breast cancer prostate cancer .</brief_summary>
	<brief_title>Assessment Pain Quality Life Breast Prostate Cancer Patients With Bone Metastases</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Inclusion criterion : Ambulatory patient &gt; 18 year Proof breast cancer prostate cancer Diagnosis least one cancerrelated bone lesion detectable conventional radiograph bone scan screen Negative pregnancy test ECOG performance status 0,1 2 Exclusion criterion : Patients abnormal renal function Patients clinically symptomatic brain metastasis Known hypersensitivity zoledronic acid bisphosphonates Pregnancy lactation Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Metastasis</keyword>
	<keyword>Neoplasm</keyword>
	<keyword>pain</keyword>
	<keyword>breast cancer</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>bone metastasis</keyword>
</DOC>